We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Cases · September 18, 2019

Metastatic Inflammatory Hormonal Positive Breast Cancer

Dr. Kawyba, AAA


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • luis betancourt

    Chemocombination. Premenop? Add OFS+ TE

  • Comment deleted by Moderator.
  • Joyce Habib

    Even if CDK4/6 inhibitor access was available, would not recommend its use for inflammatory breast cancer (excluded in MONALEESA 2,7 and MONARCH3). Given longer time to response with endocrine therapy and the high proliferative nature of disease would recommend using front-line chemotherapy in this case. She is anthracycline and taxane-naive so you have a number of options here.

  • Jan 27, 2021

    Pending Moderator approval.

Further Reading